91 related articles for article (PubMed ID: 44694)
21. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
Havemann U
Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
[No Abstract] [Full Text] [Related]
22. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.
Strange PG
Pharmacol Rev; 2001 Mar; 53(1):119-33. PubMed ID: 11171942
[TBL] [Abstract][Full Text] [Related]
23. Relative potency of some neuroleptics as antagonists at dopamine-receptors in vivo compared with their reported ability to displace haloperidol binding in vitro [proceedings].
Cox B; Ennis C; Foote G
Br J Pharmacol; 1980 Jan; 68(1):172P. PubMed ID: 6101975
[No Abstract] [Full Text] [Related]
24. [Antipsychotic drug therapy for patients with behavioral and psychological symptoms of dementia(BPSD)].
Kudo T
Seishin Shinkeigaku Zasshi; 2007; 109(7):657-63. PubMed ID: 17969953
[No Abstract] [Full Text] [Related]
25. How do antipsychotic drugs work?
Iversen LL
Neurosci Res Program Bull; 1975 Aug; 13 Suppl():29-51. PubMed ID: 241033
[No Abstract] [Full Text] [Related]
26. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
27. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
[No Abstract] [Full Text] [Related]
28. Detection of multiple receptors for dopamine.
Spano PF; Memo M; Stefanini E; Fresia P; Trabucchi M
Adv Biochem Psychopharmacol; 1980; 21():243-51. PubMed ID: 7376971
[No Abstract] [Full Text] [Related]
29. [Effect of carbidine on the dopamine and serotonin receptors of the central nervous system].
Zharkovskiĭ AM; Klassen NE; Zharkovskiĭ TA
Biull Eksp Biol Med; 1985 Jun; 99(6):700-2. PubMed ID: 2861866
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
31. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.
Scatton B
J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430
[No Abstract] [Full Text] [Related]
32. Physiological and pharmacological influences on dopaminergic receptors in the retina.
Spano PF; Govoni S; Hofmann M; Kumakura K; Trabucchi M
Adv Biochem Psychopharmacol; 1977; 16():307-10. PubMed ID: 196490
[No Abstract] [Full Text] [Related]
33. Blockade of the dopamine depressor response by molindone, a newly introduced neuroleptic.
Nandal NV; Mane VR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1980; 24(2):143-7. PubMed ID: 6103868
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological basis of therapeutics: dopamine receptors.
Heikkila RE
J Med Soc N J; 1984 Dec; 81(12):1084-6. PubMed ID: 6150999
[No Abstract] [Full Text] [Related]
35. [Dopaminergic receptors of the bladder. Study of bladder pharmacologic behavior].
Idoipe Tomás C; Idoipe Tomás JI; Sanz Sánchez F; Tarazona JV
Arch Farmacol Toxicol; 1983 Dec; 9(3):233-42. PubMed ID: 6673661
[No Abstract] [Full Text] [Related]
36. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
37. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
Creese I; Hess EJ
Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
[No Abstract] [Full Text] [Related]
38. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.
Peprah K; Zhu XY; Eyunni SV; Setola V; Roth BL; Ablordeppey SY
Bioorg Med Chem; 2012 Feb; 20(3):1291-7. PubMed ID: 22245230
[TBL] [Abstract][Full Text] [Related]
39. Agents acting on central dopamine receptors.
Kumar N; Jain PC
Prog Drug Res; 1977; 21():409-65. PubMed ID: 22892
[No Abstract] [Full Text] [Related]
40. Dopamine receptors in the brain.
Iversen LL
Science; 1975 Jun; 188(4193):1084-9. PubMed ID: 2976
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
